A company providing laboratory modules for biomedical research on the International Space Station received funding from NASA for three new projects. . . . → Read More: Retina Implant, Stem Cell Studies Set for Space Station
|
|||||
A company providing laboratory modules for biomedical research on the International Space Station received funding from NASA for three new projects. . . . → Read More: Retina Implant, Stem Cell Studies Set for Space Station An industry-academic consortium received a U.S. government contract to develop coded synthetic polymer chemicals like DNA for reliably storing massive amounts of data. . . . → Read More: Synthetic DNA Studied for Mass Data Storage Medical and robotics labs at two universities in Pittsburgh are developing a portable, autonomous trauma care device to stabilize wounded military service people in the field. . . . → Read More: A.I., Robotics Studied for Military Trauma System Two companies are developing a new model for a cloud-based platform that makes possible automated collaborative research with artificial intelligence in synthetic biology. . . . → Read More: Platform to Integrate Robotics, Synthetic Biology, A.I. The first of a series of clinical trials testing inactivated Zika particles as a vaccine to protect against the live Zika virus is recruiting participants. . . . → Read More: Zika Vaccine Clinical Trial Underway Biomedical Advanced Research and Development Authority, or BARDA, signed agreements worth $67 million to develop new treatments and diagnostics for urgent drug-resistant infections. . . . → Read More: Health Agency Funds Drug-Resistant Bacteria R&D 5 October 2015. A clinical trial testing a synthetic antibody designed to treat influenza A shows the treatment is effective in reducing the spread of flu viruses in humans. Visterra Inc., the therapy’s designer, also received a contract valued as much as $204.5 million . . . → Read More: Influenza A Therapy Shown Working in Trial 21 September 2015. Regeneron Pharmaceuticals Inc. received a contract from the U.S. Department of Health and Human Services to develop an engineered antibody designed to treat Ebola infections. The initial $17 million contract from HHS’s Biomedical Advanced Research and Development Authority . . . → Read More: Regeneron to Develop Antibody Therapy for Ebola 31 October 2014. A biodefense unit of the U.S. Department of Defense awarded a contract to vaccine maker Profectus BioSciences Inc. for development and testing of a vaccine protecting against the two major Ebola strains and related Marburg viruses. The $9.5 million contract with the . . . → Read More: Ebola-Marburg Vaccine Development, Testing Contract Awarded Enanta Pharmaceuticals, a biotechnology company in Watertown, Massachusetts, is starting an early-stage clinical trial of an antibiotic to treat methicillin-resistant Staphylococcus aureus or MRSA infections. The drug, code-named EDP-788, is being developed under a contract with National . . . → Read More: Clinical Trial to Test Safety of MRSA Drug Candidate |
|||||
Copyright © 2024 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
You must be logged in to post a comment.